Premium
PRIMARY ANALYSIS RESULTS OF THE SINGLE‐ARM PHASE II STUDY OF MOR208 PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (L‐MIND)
Author(s) -
Salles G.,
Duell J.,
González Barca E.,
Jurczak W.,
Liberati A.M.,
Nagy Z.,
Obr A.,
Gaidano G.,
Andre M.,
Kalakonda N.,
Dreyling M.,
Zinzani P.L.,
DirnbergerHertweck M.,
Weirather J.,
Ambarkhane S.,
Maddocks K.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.130_2629
Subject(s) - medicine , lenalidomide , rituximab , diffuse large b cell lymphoma , refractory (planetary science) , clinical endpoint , phases of clinical research , neutropenia , progression free survival , oncology , lymphoma , transplantation , gastroenterology , surgery , chemotherapy , clinical trial , multiple myeloma , physics , astrobiology
124 PRIMARY ANALYSIS RESULTS OF THE SINGLE-ARM PHASE II STUDY OF MOR208 PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (L-MIND) G. Salles | J. Duell | E. González Barca | W. Jurczak | A.M. Liberati | Z. Nagy | A. Obr | G. Gaidano | M. Andre | N. Kalakonda | M. Dreyling | P.L. Zinzani | M. Dirnberger-Hertweck | J. Weirather | S. Ambarkhane | K. Maddocks Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Hématologie, Pierre-Bénite, France; Medizinische Klinik und Poliklinik II, University Hospital of Würzburg, Würzburg, Germany; Department of Hematology, Institut Catalá d'Oncología, Hospital Duran i Reynals, IDIBELL, Barcelona, Spain; Department of Hematology, Jagiellonian University, Kraków, Poland; SC Oncoematologia, Azienda Ospedaliera Santa Maria, Terni, Italy; First Department of Internal Medicine, Semmelweis University, Budapest, Hungary; Department of HematoOncology, Palacký University Olomouc and the University Hospital Olomouc, Olomouc, Czech Republic; Division of Haematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy; Department of Hematology, Université catholique de Louvain, CHU UCL Namur, Yvoir, Belgium; Department of Haematooncology, Clatterbridge Cancer Centre and University of Liverpool, Wirral, United Kingdom; Department of Medicine III, University Hospital of Ludwig-Maximilians-Universität, Munich, Germany; Institute of Hematology “L. e A. Seràgnoli”, University of Bologna, Bologna, Italy; Department of Drug Safety and Pharmacovigilance, MorphoSys AG, Planegg, Germany; Department of Biostatistics and Data Management, MorphoSys AG, Planneg, Germany; Department of Clinical Development, MorphoSys AG, Planegg, Germany; Department of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States